Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesCambium Bio Ltd

Cambium Bio Ltd

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.36 AUD 0.00(0%)
Last update at 2026-11-10T23:00:00Z
Market Cap
10.60M

Momentum Score

…

Cambium Bio Limited, a clinical-stage regenerative medicine company, focuses on developing biologics for ophthalmology and tissue repair applications. The company provides Elate Ocular for the treatment of dry eye disease. The company also develops Progenza, a stem cell platform for knee osteoarthritis and other tissue repair indications; and Sygenus, for wound healing indications. Cambium Bio Limited is headquartered in Bella Vista, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.36
Low
0.36
High
52 Week Price Range
0.34
Low
0.60
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Publicly available information on Cambium Bio Ltd (ASX: CMB) is limited; the company is listed as an Australian biotechnology firm with few detailed disclosures on programs or assets. Long-term growth could depend on progress of any therapeutic development programs, intellectual property outcomes, partnerships and the company's ability to raise capital, which may benefit investors if execution succeeds.
Principal risks include the company's early-stage status and limited disclosure, significant financing and dilution risk, and high execution and regulatory uncertainty common to small biotechnology companies.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.36
Dividend Yield
-
Revenue TTM
1.23M
Revenue Per Share
0.05
Gross Profit TTM
1.04M
Debt / Equity
0.07
ROE
-194.37%
Net Debt
-0.95M
ROCE
-183.16%
Diluted EPS TTM
-0.17

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Income before tax -4.68M -3.95M -2.26M -2.67M -4.31M
Net income -4.10M -3.84M -2.26M -1.69M -4.38M
Selling general administrative - 1.57M 1.17M 1.08M 2.78M
Selling and marketing expenses - - - 0.70M -
Gross profit 0.58M 0.46M 0.00M -0.01M -0.02M
Reconciled depreciation - 0.00M 0.00M 0.01M 0.02M
Ebit - -3.81M -1.98M -2.25M -4.24M
Ebitda -4.36M -3.80M -1.98M -2.24M -4.22M
Depreciation and amortization - 0.00M 0.00M 0.01M 0.02M
Operating income -4.36M -4.30M -1.83M -2.25M -4.24M
Other operating expenses 5.00M 4.97M 1.84M 2.25M 4.65M
Interest expense 0.01M 0.03M 0.27M 0.35M 0.07M
Tax provision - 0.00M 0.00M 0.00M 0.00M
Interest income - 0.03M 0.00M 0.26M 0.00M
Net interest income - -0.00M -0.27M -0.29M -0.07M
Income tax expense -0.58M -0.10M - -0.99M 0.07M
Total revenue 0.64M 0.67M 0.00M 0.00M 0.00M
Total operating expenses 4.94M 4.76M 1.84M 2.24M 4.65M
Cost of revenue 0.06M 0.21M 0.05M 0.01M 0.02M
Total other income expense net -0.32M 0.35M -0.42M -0.42M -0.06M
Net income from continuing ops - -3.84M -2.26M -3.38M -4.31M
Net income applicable to common shares - - - -1.69M -4.31M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total assets 3.76M 3.30M 5.65M 0.71M 2.55M
Intangible assets 2.45M 2.45M 2.45M - -
Other current assets 0.02M - - 0.03M 0.03M
Total liab 1.38M 1.46M 2.87M 2.53M 1.48M
Total stockholder equity 2.38M 1.84M 2.78M -1.81M 1.07M
Other current liab 0.22M - - 0.08M 0.31M
Common stock - - - 38.62M 38.62M
Capital stock - 46.54M 43.63M 38.62M 38.62M
Retained earnings -49.21M -46.59M -42.75M -42.28M -38.95M
Other liab - - - - 0.00M
Other assets - - - - 1.75M
Cash 1.12M 0.17M 2.86M 0.30M 0.10M
Total current liabilities 1.38M 1.29M 2.40M 2.53M 1.48M
Net debt -0.95M 0.32M - 1.64M 0.91M
Short term debt 0.16M - - 1.95M 1.01M
Short long term debt - 0.32M - 1.95M 1.00M
Short long term debt total 0.16M - - 1.95M 1.01M
Other stockholder equity 51.59M - - 1.84M 1.41M
Property plant equipment - - - 0.00M 0.02M
Total current assets 1.31M 0.47M 3.20M 0.71M 0.79M
Long term investments - 0.38M - - 1.75M
Net tangible assets - - - -0.12M 1.07M
Short term investments - - - 0.00M 0.07M
Net receivables 0.17M 0.26M 0.26M 0.38M 0.56M
Long term debt - 0.17M 0.47M - -
Inventory - - - 0.00M 0.04M
Accounts payable 1.00M 0.60M 1.22M 0.50M 0.16M
Accumulated other comprehensive income - - - 1.84M 1.41M
Non currrent assets other 0.00M 0.00M 0.00M - -
Non current assets total 2.45M 2.83M 2.45M 0.00M 1.77M
Capital lease obligations - - - - 0.01M
Long term debt total - - - 0.00M 0.00M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Investments - -0.33M -0.42M -0.05M -0.01M
Change to liabilities - - - -0.01M -0.71M
Total cashflows from investing activities -0.32M -0.33M -0.42M -0.05M -0.01M
Net borrowings - - -0.35M 0.95M 1.19M
Total cash from financing activities 4.24M 2.88M 3.13M 0.92M -0.10M
Change to operating activities - - - 0.27M 0.22M
Net income -4.10M -3.84M -2.26M -1.69M -4.38M
Change in cash 0.95M -2.70M 2.56M 0.21M -3.70M
Begin period cash flow 0.17M 2.86M 0.30M 0.10M 3.79M
End period cash flow 1.12M 0.17M 2.86M 0.30M 0.10M
Total cash from operating activities -2.81M -5.24M -0.16M -0.66M -4.36M
Issuance of capital stock - 2.88M 3.48M - -
Depreciation - 0.00M 0.00M 0.01M 0.02M
Other cashflows from investing activities -0.32M -0.33M -0.42M -0.05M -
Change to account receivables 0.10M -0.00M 0.31M 0.11M -0.10M
Sale purchase of stock - - - -0.03M -
Other cashflows from financing activities -0.32M - - 1.35M 1.16M
Change to netincome - - - 0.64M 1.29M
Capital expenditures 0.00M 0.01M 0.00M 0.00M 0.01M
Change in working capital 0.36M -1.05M 1.96M 0.38M -0.59M
Other non cash items 0.92M -0.35M 0.14M 0.64M 0.59M
Free cash flow -2.81M -5.25M -0.16M -0.66M -4.37M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
CMB
Cambium Bio Ltd		 -
-%		 0.36 - 10.58 8.64 4.45 4.79 79.66
CSL
CSL Ltd		 2.86
1.42%		 204.54 - 22.57 6.15 4.48 4.82 10.06
TLX
TELIX Pharmaceuticals Ltd		 -0.32
2.28%		 13.70 93.87 166.67 5.37 6.37 3.85 47.29
NEU
Neuren Pharmaceuticals Ltd		 -0.30
1.25%		 23.66 154.93 36.36 42.38 7.52 31.95 160.40
MSB
Mesoblast Ltd		 -0.07
3.69%		 1.96 - 454.55 23.43 3.36 18.28 -9.86

Profile*

Cambium Bio Ltd

Cambium Bio Limited, a clinical-stage regenerative medicine company, focuses on developing biologics for ophthalmology and tissue repair applications. The company provides Elate Ocular for the treatment of dry eye disease. The company also develops Progenza, a stem cell platform for knee osteoarthritis and other tissue repair indications; and Sygenus, for wound healing indications. Cambium Bio Limited is headquartered in Bella Vista, Australia.

Unit 2.06/31 Lexington Dr, Bella Vista, NSW, Australia, 2153

61 13 0099 5098

https://www.cambium.bio

Name Title Year Born
Mr. Karolis Rosickas Chief Executive Officer NA
Prof. Graham Vesey Ph.D. Chief Scientific Officer & Executive Director 1965
Dr. Charlotte Morgan Ph.D. Head of Research & Development NA
Ling Leung Hang Company Secretary NA
Mr. Karolis Rosickas M.B.A., M.S. Chief Executive Officer NA
Dr. Edmund Kemp Waller FACP, M.D., Ph.D. Chief Scientific Officer & Executive Director NA
Mr. Terence Allen Walts Executive Director 1948
Hang Ling Leung Company Secretary NA
Dr. Edmund Kemp Waller FACP, M.D., Ph.D. Chairman & Chief Scientific Officer NA
Mr. Mark Andrew Licciardo B Bus (Acc), FCIS, FGIA, GAICD, GradDip CSP Company Secretary 1964

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

MAL
CAD 38.85
+13.53%
SOIL
CAD 8.39
+12.02%
QNC
CAD 1.48
+10.45%
TCL-B
CAD 7.26
+9.01%
CLS
CAD 345.53
+8.41%
GSY
CAD 37.75
-16.04%
BYD
CAD 109.98
-11.99%
ELE
CAD 20.12
-11.95%
LAC
CAD 2.39
-11.15%
CFW
CAD 6.51
-10.82%

Equity Sectors*

  • Basic Materials

    -1.75%

  • Communication Services

    +0.20%

  • Consumer Cyclical

    +0.18%

  • Consumer Defensive

    +0.06%

  • Energy

    +1.65%

  • Financial Services

    +0.10%

  • Healthcare

    +1.25%

  • Industrials

    +1.60%

  • Real Estate

    -0.29%

  • Technology

    +2.72%

  • Utilities

    +0.12%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…